Evonik Full-Year Report 2023
A Challenging Year
- Lower demand as a result of the weak economic environment
- Selling prices stable in the specialty chemicals businesses but significant declines at Animal Nutrition and Performance Intermediates
- Sales decreased by 17 percent to €15.3 billion, mainly due to volumes
- Adjusted EBITDA fell 33 percent to €1.7 billion
- High free cash flow of €801 million
- Adjusted net income 65 percent below the prior-year level at €370 million
- Net income was -€465 million as a consequence of high impairment losses
- Outlook for 2024: adjusted EBITDA expected to be between €1.7 billion and €2.0 billion